Nancy Bello, DO
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 43.5% of the total. Reporting peaked in 2019 at $202 and has fallen 90.5% since, to $19 in 2025. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 22 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$260
- AstraZeneca$168
- GSK$65
- Ipsen Biopharmaceuticals, Inc$34
- Argenx US, Inc.$22
- Mallinckrodt Hospital Products Inc.$18
- plus $31 from 2 others
What the payments were for
- Food & beverage$599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $260 |
| AstraZeneca | 3 | $168 |
| GSK | 4 | $65 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Argenx US, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$599 in reported general payments places this provider in the 35th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $299,056 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,656 |
| Lacosamide | 13 | $1,796 |
| Levetiracetam | 34 | $1,703 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $1,268 |
| Propranolol Hcl | 32 | $1,101 |
| Donepezil Hcl | 50 | $1,043 |
| Carbamazepine | 11 | $234 |
| Sumatriptan Succinate | 15 | $168 |
Paid to pharmacies, not to this prescriber.
Other neurology in Yuma
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Jonathan HodgsonGilbert$408K
- Lori TravisPhoenix$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.